Government-Owned Inventions; Availability for Licensing, 43216-43218 [2013-17319]
Download as PDF
<![CDATA[
43216
Federal Register / Vol. 78, No. 139 / Friday, July 19, 2013 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS—Continued
Number of
respondents
Form name
Type of respondent
Paper/pen, CAWI or CATI .................
Paper/pen, CAWI or CATI .................
Spouses ...........................................
Proxy ................................................
Dated: July 10, 2013.
Rick Woychik,
Deputy Director, NIEHS.
[FR Doc. 2013–17362 Filed 7–18–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 209 and 37 CFR Part 404 to
achieve expeditious commercialization
of results of federally-funded research
and development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
U.S. patent applications listed below
may be obtained by writing to the
indicated licensing contact at the Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
emcdonald on DSK67QTVN1PROD with NOTICES
SUMMARY:
Use of Cysteamine to Treat Metastatic
Cancer
Description of Technology:
Cysteamine is an aminothiol and antioxidant that has potential for the
treatment of radiation sickness,
neurological disorders and cancer.
Cysteamine has FDA approval for use in
humans, and produces few side-effects
as a natural degradation product of an
essential amino acid. It is mostly used
for treatment of cystinosis. The
inventors on this technology have
demonstrated that cysteamine also
VerDate Mar<15>2010
15:33 Jul 18, 2013
Jkt 229001
10,201
635
suppresses the activity of matrix
metalloproteinases (MMPs). Because
MMPs have been implicated in tumor
invasion and metastasis, cysteamine has
potential as an effective therapeutic for
metastatic cancer. Administration of
cysteamine was able to reduce invasion
and metastasis in mouse xenograft
tumor models and prolong survival of
the mice without significant adverse
side effects. This suggests that
cysteamine could represent a novel
therapeutic agent for treatment of
metastatic cancer.
Potential Commercial Applications:
Therapeutic for metastatic cancer as
monotherapy or combined with other
drugs.
Competitive Advantages:
• Cysteamine does not produce
adverse side-effects when administered
to humans.
• Cysteamine has already been
approved for use in humans, providing
a clearer path to clinical approval.
Development Stage:
• Pre-clinical.
• In vitro data available.
• In vivo data available (animal).
Inventors: Raj K. Puri and Bharat Joshi
(CBER/FDA).
Publication: Fujisawa T, et al.
Cysteamine suppresses invasion,
metastasis and prolongs survival by
inhibiting matrix metalloproteinases in
a mouse model of human pancreatic
cancer. PLoS One. 2012;7(4):e34437.
[PMID 22532830]
Intellectual Property: HHS Reference
No. E–219–2013/0—
• US Provisional Application No. 61/
814,010.
• Canadian Application No. 2813514.
• Australian Application No.
2013205350.
• Korean Application No. 10–2013–
43713.
Licensing Contact: David A.
Lambertson, Ph.D.; 301–435–4632;
lambertsond@mail.nih.gov.
Encircling Suture Delivery System
Description of Technology: The
invention provides a novel delivery
system for delivering an encircling
suture which includes two separate
hollow limbs held together at an
articulation by the suture to be
PO 00000
Frm 00077
Fmt 4703
Sfmt 4703
Number of
responses per
respondent
1
1
Average
burden per
response
(in hours)
25/60
15/60
Total annual
burden hours
4,250
159
delivered. The suture can extend
through the hollow limbs, which slide
along the suture. The distal ends of the
limbs can be compressed into a desired
delivery shape that allows the limbs to
be advanced through the lumen of a
delivery catheter (e.g., a transcutaneous,
transvascular or intraluminal catheter)
into any body cavity. As the distal
portions of the limbs move out of the
delivery catheter, the limbs
cooperatively assume a loop shape
complementary to the shape of the
target around the encircling suture to
leave only the suture in the desired
delivery position while maintaining
desired suture tension and position. The
delivery device can be placed around a
variety of anatomical structures (e.g.,
heart, arterial appendage, cecal
appendix, gall bladder, neoplasm,
uterus, hemorrhoid, uvula, aneurysm,
transected blood vessel, folded or
looped lumen, intraocular crystalline
lens or implated intraocular lens or
haptic, urinary bladder, kidney,
prostate, intestine, or liver, etc.).
Potential Commercial Applications:
• Surgery.
• Suturing.
• Catheterization.
• Cardiac valve repair.
Competitive Advantages:
• Formable suturing.
• Circumferential suturing.
• Flexible.
• Easy to use.
Development Stage: Prototype.
Inventors: Toby Rogers, Robert
Lederman, Merdim Sonmez, Dominique
Franson, Ozgur Kocaturk (all of NHLBI).
Intellectual Property: HHS Reference
No. E–115–2013/0—US Provisional
Patent Application 61/834,357 filed
June 12, 2013.
Related Technologies:
• HHS Reference No. E–027–2013/
0—Devices and Methods for Treating
Functional Tricuspid Valve
Regurgitation.
• HHS Reference No. E–112–2010/
0—Target and Capture Device for
Transcatheter Cerclage Annuloplasty.
• HHS Reference No. E–108–2010/
0—An Expandable Mesh Target and
Capture Device for Transcatheter
Cerciage Annuloplasty.
E:\FR\FM\19JYN1.SGM
19JYN1
Federal Register / Vol. 78, No. 139 / Friday, July 19, 2013 / Notices
emcdonald on DSK67QTVN1PROD with NOTICES
Licensing Contact: Michael
Shmilovich; 301–435–5019;
shmilovm@mail.nih.gov.
Peptide Inhibitors of Polo-like Kinase 1
(PLK1) Useful as Anti-cancer
Therapeutics
Description of Technology: PLK1 is
being studied as a target for cancer
drugs. Many colon and lung cancers are
caused by KRAS mutations. These
cancers are dependent on PLK1.
Inhibition of PLK1 allows for selective
killing of cancer cells without harm to
normal cells. The peptide derivatives
available for licensing have achieved
both good efficacy and enhanced
bioavailability.
Potential Commercial Applications:
Development of selective cancer
therapeutics.
Competitive Advantages: Enhanced
bioavailability and higher binding
efficacy over existing peptide PLK1
ligands.
Development Stage: Early-stage.
Inventors: Terrence R. Burke, Fa Liu,
Wen-Jian Qian, Jung-Eun Park, Kyung S.
Lee (all of NCI).
Publications:
1. Liu F, et al. Serendipitous
alkylation of a Plk1 ligand uncovers a
new binding channel. Nat Chem Biol.
2011 Jul 17;7(9):595–601. [PMID
21765407].
2. Qian W, et al. Investigation of
unanticipated alkylation at the N(p)
position of a histidyl residue under
Mitsunobu conditions and synthesis of
orthogonally protected histidine
analogues. J Org Chem. 2011 Nov
4;76(21):8885–90. [PMID 21950469].
3. Liu F, et al. Identification of high
affinity polo-like kinase 1 (Plk1) polobox domain binding peptides using
oxime-based diversification. ACS Chem
Biol. 2012 May 18;7(5):805–10. [PMID
22292814].
4. Liu F, et al. Peptoid-Peptide hybrid
ligands targeting the polo box domain of
polo-like kinase 1. Chembiochem. 2012
Jun 18;13(9):1291–6. [PMID 22570300].
5. Qian W, et al. Effects on polo-like
kinase 1 polo-box domain binding
affinities of peptides incurred by
structural variation at the
phosphoamino acid position. Bioorg
Med Chem. 2013 Jul 15;21(14):3996–
4003. [PMID 22743087].
6. Qian W, et al. Non-proteinogenic
amino acids in the pThr–2 position of
a pentamer peptide that confer high
binding affinity for the polo box domain
(PBD) of polo-like kinase 1 (Plk1).
Bioorg Med Chem Lett. 2012 Dec
15;22(24):7306–8. [PMID 23159568].
Intellectual Property: HHS Reference
No. E–094–2013/0—US Application No.
61/784,971 filed March 14, 2013.
VerDate Mar<15>2010
15:33 Jul 18, 2013
Jkt 229001
Related Technologies: HHS Reference
Nos. E–181–2009/0, E–181–2009/1, E–
181–2009/3, E–181–2009/4, E–053–
2012/0—Development of Peptide
Mimetic Ligands of Polo-like Kinase 1
Polo Box Domain.
Licensing Contact: Patrick McCue,
Ph.D.; 301–435–5560;
mccuepat@mail.nih.gov.
Polymeric Silicone Hydrogel Vessel
Mimetics for Cell Culturing
Description of Technology: The
invention pertains to high oxygen
diffusivity silicone hydrogel support
structures that mimic tissue vasculature
(e.g., capillary bed). Photolithographic
methods are used to construct mimetic
silicone hydrogel pillars that have, for
example, a 20:1 height to diameter ratio.
Advantageously, these mimetic silicone
hydrogels diffuse oxygen from the
bottom chamber to the cells cultured on
the surface at near physiological rates
(60 times that of water). Uses of these
mimetics include 2–D screening for
chemotherapeutic compounds and
growth of tissue for grafting.
Potential Commercial Applications:
• Tissue engineering.
• Simulation of physiological growth
conditions.
Competitive Advantages: High oxygen
diffusivity.
Development Stage:
• Prototype.
• Pilot.
• In vitro data available.
Inventors: Chandan Das (NCI), Ashley
Jaeger (CIT), Thomas Pohida (CIT),
Randall Pursley (CIT), Philip McQueen
(CIT), Nicole Morgan (NIBIB), Michael
Gottesman (NCI).
Intellectual Property:
• HHS Reference No. E–070–2013/
0—US Provisional Patent Application
61/758,198 filed January 29, 2013.
• HHS Reference No. E–070–2013/
1—US Provisional Patent Application
61/773,064 filed March 5, 2013.
Licensing Contact: Michael
Shmilovich; 301–435–5019;
shmilovm@mail.nih.gov.
Co-Transcriptional Assembly of
Modified RNA Nanoparticles
Description of Technology: A method
is provided for generating RNA
nanoparticles having modified
nucleotides and/or having increased
nuclease resistance where the RNA
nanoparticles are formed cotranscriptionally by T7 RNA polymerase
in the presence of manganese ions.
Potential Commercial Applications:
Inexpensive and efficient method of
producing chemically modified RNA
nanoparticles for diagnostic or
therapeutic applications.
PO 00000
Frm 00078
Fmt 4703
Sfmt 4703
43217
Competitive Advantages:
• Overcomes the cost and size
limitations of solid-phase RNA
synthesis.
• Allows complexity of RNA
nanoparticles production.
• Increases retention time of RNA
nanoparticles.
Development Stage:
• Early-stage.
• In vitro data available.
Inventors: Bruce A. Shapiro (NCI),
Kirill Afonin (NCI), Maria Kireeva (NCI),
Mikhail Kashlev (NCI), Luc Jaeger (Univ
California, Santa Barbara), Wade
Grabow (Univ California, Santa
Barbara).
Publications:
1. Afonin KA, et al. Co-transcriptional
assembly of chemically modified RNA
nanoparticles functionalized with
siRNAs. Nano Lett. 2012 Oct
10;12(10):5192–5. [PMID 23016824].
2. Grabow WW, et al. ‘‘RNA
Nanotechnology in Nanomedicine,’’ in
Nanomedicine and Drug Delivery
(Recent Advances in Nanoscience and
Nanotechnology), ed. M Sebastian, et al.
(New Jersey: Apple Academic Press,
2012), 208–220. [Book Chapter].
3. Shukla GC, et al. A boost for the
emerging field of RNA nanotechnology.
ACS Nano. 2011 May 24;5(5):3405–18.
[PMID 21604810].
4. Afonin KA, et al. Design and selfassembly of siRNA-functionalized RNA
nanoparticles for use in automated
nanomedicine. Nat Protoc. 2011 Dec
1;6(12):2022–34. [PMID 22134126].
5. Bindewald E, et al. Multistrand
RNA secondary structure prediction and
nanostructure design including
pseudoknots. ACS Nano. 2011 Dec
27;5(12):9542–51. [PMID 22067111].
6. Grabow WW, et al. Self-assembling
RNA nanorings based on RNAI/II
inverse kissing complexes. Nano Lett.
2011 Feb 9;11(2):878–87. [PMID
21229999].
7. Kasprzak W, et al. Use of RNA
structure flexibility data in
nanostructure modeling. Methods. 2011
Jun;54(2):239–50. [PMID 21163354].
Intellectual Property: HHS Reference
No. E–223–2012/0—US Provisional
Application No. 61/698,227 filed 07 Sep
2012.
Related Technologies:
• HHS Reference No. E–059–2009/
0—International Application No. PCT/
US2010/038818.
• HHS Reference No. E–038–2012/
0—International Application No. PCT/
US2012/065932.
• HHS Reference No. E–039–2012/
0—International Application No. PCT/
US2012/065945.
Licensing Contact: John Stansberry;
301–435–5236; stansbej@mail.nih.gov.
E:\FR\FM\19JYN1.SGM
19JYN1
43218
Federal Register / Vol. 78, No. 139 / Friday, July 19, 2013 / Notices
Collaborative Research Opportunity:
The NCI Center for Cancer Research
Nanobiology is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize diagnostic or therapeutic
RNA nanoparticles. For collaboration
opportunities, please contact John
Hewes, Ph.D. at hewesj@mail.nih.gov.
Dated: July 12, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2013–17319 Filed 7–18–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Notice of Kidney Interagency
Coordinating Committee Meeting
The Kidney Interagency
Coordinating Committee (KICC) will
hold a meeting on September 27, 2013,
about interagency collaboration to
improve outcomes in Chronic Kidney
Disease (CKD). The meeting is open to
the public.
DATES: The meeting will be held on
September 27, 2013, 9 a.m. to 12 p.m.
Individuals wanting to present oral
comments must notify the contact
person at least 10 days before the
meeting date.
ADDRESSES: The meeting will be held at
the Natcher Conference Center (Building
45), on the NIH Campus at 8600
Rockville Pike, Bethesda, MD 20894.
FOR FURTHER INFORMATION CONTACT: For
further information concerning this
meeting, contact Dr. Andrew S. Narva,
Executive Secretary of the Kidney
Interagency Coordinating Committee,
National Institute of Diabetes and
Digestive and Kidney Diseases, 31
Center Drive, Building 31A, Room
9A26, MSC 2560, Bethesda, MD 20892–
2560, telephone: 301–594–8864; FAX:
301–480–0243; email:
nkdep@info.niddk.nih.gov.
SUPPLEMENTARY INFORMATION: The KICC,
chaired by the National Institute of
Diabetes and Digestive and Kidney
Diseases (NIDDK), comprises members
of the Department of Health and Human
Services and other federal agencies that
support kidney-related activities,
facilitates cooperation, communication,
and collaboration on kidney disease
among government entities. KICC
meetings, held twice a year, provide an
opportunity for Committee members to
emcdonald on DSK67QTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
15:33 Jul 18, 2013
Jkt 229001
learn about and discuss current and
future kidney programs in KICC member
organizations and to identify
opportunities for collaboration. The
September 27, 2013 KICC meeting will
focus on interagency collaboration to
improve outcomes in CKD.
Any member of the public interested
in presenting oral comments to the
Committee should notify the contact
person listed on this notice at least 10
days in advance of the meeting.
Interested individuals and
representatives or organizations should
submit a letter of intent, a brief
description of the organization
represented, and a written copy of their
oral presentation in advance of the
meeting. Only one representative of an
organization will be allowed to present;
oral comments and presentations will be
limited to a maximum of 5 minutes.
Printed and electronic copies are
requested for the record. In addition,
any interested person may file written
comments with the Committee by
forwarding their statement to the
contact person listed on this notice. The
statement should include the name,
address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Because of time constraints for the
meeting, oral comments will be allowed
on a first-come, first-serve basis.
Members of the public who would
like to receive email notification about
future KICC meetings should send a
request to nkdep@info.niddk.nih.gov.
Dated: July 8, 2013.
Camille Hoover,
Executive Officer, National Institute of
Diabetes and Digestive and Kidney Diseases,
National Institutes of Health.
[FR Doc. 2013–17360 Filed 7–18–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
PO 00000
Frm 00079
Fmt 4703
Sfmt 9990
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Immune Mechanism.
Date: July 30, 2013.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Scott Jakes, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4198,
MSC 7812, Bethesda, MD 20892, 301–495–
1506, jakesse@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; RFA–OD–
13–005: Restoration of New Investigator Pilot
Projects Adversely Affected by Hurricane
Sandy.
Date: August 14, 2013.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Weihua Luo, MD, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5114,
MSC 7854, Bethesda, MD 20892, (301) 435–
1170, luow@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Vascular
Hematology.
Date: August 14, 2013.
Time: 2:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Bukhtiar H Shah, DVM,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4120,
MSC 7802, Bethesda, MD 20892, 301–806–
7314, shahb@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: July 15, 2013.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–17320 Filed 7–18–13; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\19JYN1.SGM
19JYN1
]]>Agencies
[Federal Register Volume 78, Number 139 (Friday, July 19, 2013)]
[Notices]
[Pages 43216-43218]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-17319]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 209 and 37 CFR Part 404 to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the U.S. patent applications listed below may be obtained by writing to
the indicated licensing contact at the Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-
0220. A signed Confidential Disclosure Agreement will be required to
receive copies of the patent applications.
Use of Cysteamine to Treat Metastatic Cancer
Description of Technology: Cysteamine is an aminothiol and anti-
oxidant that has potential for the treatment of radiation sickness,
neurological disorders and cancer. Cysteamine has FDA approval for use
in humans, and produces few side-effects as a natural degradation
product of an essential amino acid. It is mostly used for treatment of
cystinosis. The inventors on this technology have demonstrated that
cysteamine also suppresses the activity of matrix metalloproteinases
(MMPs). Because MMPs have been implicated in tumor invasion and
metastasis, cysteamine has potential as an effective therapeutic for
metastatic cancer. Administration of cysteamine was able to reduce
invasion and metastasis in mouse xenograft tumor models and prolong
survival of the mice without significant adverse side effects. This
suggests that cysteamine could represent a novel therapeutic agent for
treatment of metastatic cancer.
Potential Commercial Applications: Therapeutic for metastatic
cancer as monotherapy or combined with other drugs.
Competitive Advantages:
Cysteamine does not produce adverse side-effects when
administered to humans.
Cysteamine has already been approved for use in humans,
providing a clearer path to clinical approval.
Development Stage:
Pre-clinical.
In vitro data available.
In vivo data available (animal).
Inventors: Raj K. Puri and Bharat Joshi (CBER/FDA).
Publication: Fujisawa T, et al. Cysteamine suppresses invasion,
metastasis and prolongs survival by inhibiting matrix
metalloproteinases in a mouse model of human pancreatic cancer. PLoS
One. 2012;7(4):e34437. [PMID 22532830]
Intellectual Property: HHS Reference No. E-219-2013/0--
US Provisional Application No. 61/814,010.
Canadian Application No. 2813514.
Australian Application No. 2013205350.
Korean Application No. 10-2013-43713.
Licensing Contact: David A. Lambertson, Ph.D.; 301-435-4632;
lambertsond@mail.nih.gov.
Encircling Suture Delivery System
Description of Technology: The invention provides a novel delivery
system for delivering an encircling suture which includes two separate
hollow limbs held together at an articulation by the suture to be
delivered. The suture can extend through the hollow limbs, which slide
along the suture. The distal ends of the limbs can be compressed into a
desired delivery shape that allows the limbs to be advanced through the
lumen of a delivery catheter (e.g., a transcutaneous, transvascular or
intraluminal catheter) into any body cavity. As the distal portions of
the limbs move out of the delivery catheter, the limbs cooperatively
assume a loop shape complementary to the shape of the target around the
encircling suture to leave only the suture in the desired delivery
position while maintaining desired suture tension and position. The
delivery device can be placed around a variety of anatomical structures
(e.g., heart, arterial appendage, cecal appendix, gall bladder,
neoplasm, uterus, hemorrhoid, uvula, aneurysm, transected blood vessel,
folded or looped lumen, intraocular crystalline lens or implated
intraocular lens or haptic, urinary bladder, kidney, prostate,
intestine, or liver, etc.).
Potential Commercial Applications:
Surgery.
Suturing.
Catheterization.
Cardiac valve repair.
Competitive Advantages:
Formable suturing.
Circumferential suturing.
Flexible.
Easy to use.
Development Stage: Prototype.
Inventors: Toby Rogers, Robert Lederman, Merdim Sonmez, Dominique
Franson, Ozgur Kocaturk (all of NHLBI).
Intellectual Property: HHS Reference No. E-115-2013/0--US
Provisional Patent Application 61/834,357 filed June 12, 2013.
Related Technologies:
HHS Reference No. E-027-2013/0--Devices and Methods for
Treating Functional Tricuspid Valve Regurgitation.
HHS Reference No. E-112-2010/0--Target and Capture Device
for Transcatheter Cerclage Annuloplasty.
HHS Reference No. E-108-2010/0--An Expandable Mesh Target
and Capture Device for Transcatheter Cerciage Annuloplasty.
[[Page 43217]]
Licensing Contact: Michael Shmilovich; 301-435-5019;
shmilovm@mail.nih.gov.
Peptide Inhibitors of Polo-like Kinase 1 (PLK1) Useful as Anti-cancer
Therapeutics
Description of Technology: PLK1 is being studied as a target for
cancer drugs. Many colon and lung cancers are caused by KRAS mutations.
These cancers are dependent on PLK1. Inhibition of PLK1 allows for
selective killing of cancer cells without harm to normal cells. The
peptide derivatives available for licensing have achieved both good
efficacy and enhanced bioavailability.
Potential Commercial Applications: Development of selective cancer
therapeutics.
Competitive Advantages: Enhanced bioavailability and higher binding
efficacy over existing peptide PLK1 ligands.
Development Stage: Early-stage.
Inventors: Terrence R. Burke, Fa Liu, Wen-Jian Qian, Jung-Eun Park,
Kyung S. Lee (all of NCI).
Publications:
1. Liu F, et al. Serendipitous alkylation of a Plk1 ligand uncovers
a new binding channel. Nat Chem Biol. 2011 Jul 17;7(9):595-601. [PMID
21765407].
2. Qian W, et al. Investigation of unanticipated alkylation at the
N([pi]) position of a histidyl residue under Mitsunobu conditions and
synthesis of orthogonally protected histidine analogues. J Org Chem.
2011 Nov 4;76(21):8885-90. [PMID 21950469].
3. Liu F, et al. Identification of high affinity polo-like kinase 1
(Plk1) polo-box domain binding peptides using oxime-based
diversification. ACS Chem Biol. 2012 May 18;7(5):805-10. [PMID
22292814].
4. Liu F, et al. Peptoid-Peptide hybrid ligands targeting the polo
box domain of polo-like kinase 1. Chembiochem. 2012 Jun 18;13(9):1291-
6. [PMID 22570300].
5. Qian W, et al. Effects on polo-like kinase 1 polo-box domain
binding affinities of peptides incurred by structural variation at the
phosphoamino acid position. Bioorg Med Chem. 2013 Jul 15;21(14):3996-
4003. [PMID 22743087].
6. Qian W, et al. Non-proteinogenic amino acids in the pThr-2
position of a pentamer peptide that confer high binding affinity for
the polo box domain (PBD) of polo-like kinase 1 (Plk1). Bioorg Med Chem
Lett. 2012 Dec 15;22(24):7306-8. [PMID 23159568].
Intellectual Property: HHS Reference No. E-094-2013/0--US
Application No. 61/784,971 filed March 14, 2013.
Related Technologies: HHS Reference Nos. E-181-2009/0, E-181-2009/
1, E-181-2009/3, E-181-2009/4, E-053-2012/0--Development of Peptide
Mimetic Ligands of Polo-like Kinase 1 Polo Box Domain.
Licensing Contact: Patrick McCue, Ph.D.; 301-435-5560;
mccuepat@mail.nih.gov.
Polymeric Silicone Hydrogel Vessel Mimetics for Cell Culturing
Description of Technology: The invention pertains to high oxygen
diffusivity silicone hydrogel support structures that mimic tissue
vasculature (e.g., capillary bed). Photolithographic methods are used
to construct mimetic silicone hydrogel pillars that have, for example,
a 20:1 height to diameter ratio. Advantageously, these mimetic silicone
hydrogels diffuse oxygen from the bottom chamber to the cells cultured
on the surface at near physiological rates (60 times that of water).
Uses of these mimetics include 2-D screening for chemotherapeutic
compounds and growth of tissue for grafting.
Potential Commercial Applications:
Tissue engineering.
Simulation of physiological growth conditions.
Competitive Advantages: High oxygen diffusivity.
Development Stage:
Prototype.
Pilot.
In vitro data available.
Inventors: Chandan Das (NCI), Ashley Jaeger (CIT), Thomas Pohida
(CIT), Randall Pursley (CIT), Philip McQueen (CIT), Nicole Morgan
(NIBIB), Michael Gottesman (NCI).
Intellectual Property:
HHS Reference No. E-070-2013/0--US Provisional Patent
Application 61/758,198 filed January 29, 2013.
HHS Reference No. E-070-2013/1--US Provisional Patent
Application 61/773,064 filed March 5, 2013.
Licensing Contact: Michael Shmilovich; 301-435-5019;
shmilovm@mail.nih.gov.
Co-Transcriptional Assembly of Modified RNA Nanoparticles
Description of Technology: A method is provided for generating RNA
nanoparticles having modified nucleotides and/or having increased
nuclease resistance where the RNA nanoparticles are formed co-
transcriptionally by T7 RNA polymerase in the presence of manganese
ions.
Potential Commercial Applications: Inexpensive and efficient method
of producing chemically modified RNA nanoparticles for diagnostic or
therapeutic applications.
Competitive Advantages:
Overcomes the cost and size limitations of solid-phase RNA
synthesis.
Allows complexity of RNA nanoparticles production.
Increases retention time of RNA nanoparticles.
Development Stage:
Early-stage.
In vitro data available.
Inventors: Bruce A. Shapiro (NCI), Kirill Afonin (NCI), Maria
Kireeva (NCI), Mikhail Kashlev (NCI), Luc Jaeger (Univ California,
Santa Barbara), Wade Grabow (Univ California, Santa Barbara).
Publications:
1. Afonin KA, et al. Co-transcriptional assembly of chemically
modified RNA nanoparticles functionalized with siRNAs. Nano Lett. 2012
Oct 10;12(10):5192-5. [PMID 23016824].
2. Grabow WW, et al. ``RNA Nanotechnology in Nanomedicine,'' in
Nanomedicine and Drug Delivery (Recent Advances in Nanoscience and
Nanotechnology), ed. M Sebastian, et al. (New Jersey: Apple Academic
Press, 2012), 208-220. [Book Chapter].
3. Shukla GC, et al. A boost for the emerging field of RNA
nanotechnology. ACS Nano. 2011 May 24;5(5):3405-18. [PMID 21604810].
4. Afonin KA, et al. Design and self-assembly of siRNA-
functionalized RNA nanoparticles for use in automated nanomedicine. Nat
Protoc. 2011 Dec 1;6(12):2022-34. [PMID 22134126].
5. Bindewald E, et al. Multistrand RNA secondary structure
prediction and nanostructure design including pseudoknots. ACS Nano.
2011 Dec 27;5(12):9542-51. [PMID 22067111].
6. Grabow WW, et al. Self-assembling RNA nanorings based on RNAI/II
inverse kissing complexes. Nano Lett. 2011 Feb 9;11(2):878-87. [PMID
21229999].
7. Kasprzak W, et al. Use of RNA structure flexibility data in
nanostructure modeling. Methods. 2011 Jun;54(2):239-50. [PMID
21163354].
Intellectual Property: HHS Reference No. E-223-2012/0--US
Provisional Application No. 61/698,227 filed 07 Sep 2012.
Related Technologies:
HHS Reference No. E-059-2009/0--International Application
No. PCT/US2010/038818.
HHS Reference No. E-038-2012/0--International Application
No. PCT/US2012/065932.
HHS Reference No. E-039-2012/0--International Application
No. PCT/US2012/065945.
Licensing Contact: John Stansberry; 301-435-5236;
stansbej@mail.nih.gov.
[[Page 43218]]
Collaborative Research Opportunity: The NCI Center for Cancer
Research Nanobiology is seeking statements of capability or interest
from parties interested in collaborative research to further develop,
evaluate or commercialize diagnostic or therapeutic RNA nanoparticles.
For collaboration opportunities, please contact John Hewes, Ph.D. at
hewesj@mail.nih.gov.
Dated: July 12, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2013-17319 Filed 7-18-13; 8:45 am]
BILLING CODE 4140-01-P
